Expression of apolipoprotein M and its association with adiponectin in an obese mouse model

Yang,Liu; Li,Tie; Zhao,Shuiping; Zhang,Saidan

doi:10.3892/etm.2019.7755

Expression of apolipoprotein M and its association with adiponectin in an obese mouse model

Authors:
- Liu Yang
- Tie Li
- Shuiping Zhao
- Saidan Zhang
View Affiliations

Affiliations: International Medical Center, Geriatric Department, National Clinical Research Center of Geriatric Diseases, Xiangya Hospital of Central South University, Changsha, Hunan 410008, P.R. China, Department of Cardiology, Changsha Central Hospital, Changsha, Hunan 410000, P.R. China, Department of Cardiology, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, P.R. China, Department of Cardiology, Xiangya Hospital of Central South University, Changsha, Hunan 410008, P.R. China
Published online on: July 9, 2019 https://doi.org/10.3892/etm.2019.7755
Pages: 1685-1692
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to explore the association between apolipoprotein M (ApoM) and adiponectin, and the underlying mechanism, via observation of ApoM expression in an obese mouse model. For in vivo experiments, mice were randomly distributed into four groups: Control group, obese group, obese group treated with adiponectin, and normal group treated with adiponectin. Body weight, plasma adiponectin, blood glucose and fasting insulin were measured and visceral adipose tissue was weighed at the end of the experiment. ApoM and transcription factor forkhead box A2 (Foxa2) mRNA expression in the mouse liver was evaluated and the protein level of ApoM detected. For in vitro experiments, an insulin‑resistant (IR) hepatic cell model was established by inducing the HepG2 cell line with a high concentration of insulin. Following treatment with adiponectin, changes in ApoM and Foxa2 mRNA expression and ApoM protein expression were evaluated in the control and IR HepG2 cells. Results demonstrated that compared with the control group, body weight, visceral adipose tissue weight, blood glucose, fasting insulin and insulin‑resistance index (HOMA‑IR) were significantly increased in the obese group, whilst plasma adiponectin, ApoM mRNA expression, Foxa2 mRNA expression and ApoM protein in the mouse liver were all significantly decreased. Following intervention with adiponectin in obese mice, blood glucose, insulin and HOMA‑IR were significantly decreased, whilst plasma adiponectin, ApoM mRNA expression, Foxa2 mRNA expression and ApoM protein were all significantly increased. However, no significant difference was observed in visceral adipose tissue weight following the intervention of adiponectin in obese mice. In vitro, in the absence of intervention, ApoM and Foxa2 mRNA expression and ApoM protein expression were significantly lower in IR HepG2 cells compared with HepG2 cells. Following intervention with adiponectin on IR HepG2 cells, ApoM and Foxa2 mRNA expression and ApoM protein expression were significantly increased. However, the intervention did not have any effect on HepG2 cells. In conclusion, intervention with adiponectin elevated ApoM mRNA expression, potentially via relieving IR and upregulating Foxa2 mRNA expression.

View Figures

View References

1	Ravussin A and Bouchard C: Human genomics and obesity: Finding appropriate drug targets. Eur J Pharmacol. 410:131–145. 2000. View Article : Google Scholar : PubMed/NCBI
2	Abbasi F, Brown BW Jr, Lamendola C, McLaughlin T and Reaven GM: Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol. 40:937–943. 2002. View Article : Google Scholar : PubMed/NCBI
3	Sacks FM; Expert Group on HDL Cholesterol, : The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: Expert group recommendations. AM J cardiol. 90:139–143. 2002. View Article : Google Scholar : PubMed/NCBI
4	Wolfrum C, Poy MN and Stoffel M: Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. Nat Med. 11:418–422. 2005. View Article : Google Scholar : PubMed/NCBI
5	Everson SA, Goldbeng DE, Helmrich SP, Lakka TA, Lynch JW, Kaplan GA and Salonen JT: Weight gain and the risk of developing insulin resistance syndrome. Diabetes Care. 21:1637–1643. 1998. View Article : Google Scholar : PubMed/NCBI
6	Caro JF: Clinical review 26: Insulin resistance in obese and nonobese man. J Clin Endocrinol Metab. 73:691–695. 1991. View Article : Google Scholar : PubMed/NCBI
7	Podskalny JM, Takeda S, Silverman RE, Tran D, Carpentier JL, Orci L and Gorden P: Insulin receptors and bioresponses in a human liver cell line (Hep G-2). Eur J Biochem. 1502:401–407. 1985. View Article : Google Scholar
8	Brillon DJ, Freidenberg GR, Henry RR and Olefsky JM: Mechanism of defective insulin-receptor kinase activity in NIDDM. Evidence for two receptor populations. Diabetes. 38:397–403. 1989. View Article : Google Scholar : PubMed/NCBI
9	Hari J and Roth RA: Defective internalization of insulin and its receptor in cells expressing mutated insulin receptors lacking kinase activity. J Biol Chem. 262:15341–15344. 1987.PubMed/NCBI
10	Amatruda JM and Roncone AM: Normal hepatic insulin receptor autophosphorylation in nonketotic diabetes mellitus. Biochem Biophys Res Commun. 129:163–170. 1985. View Article : Google Scholar : PubMed/NCBI
11	Changgui L, Guang N and Jialun C: Establishing and identifing insulin resistant HepG2 cell line. Chin J Diabetes. 7:198–199. 1999.
12	Xie P, Liu ML, Gu YP, Lu J, Xu X, Zeng WM and Song HP: Oestrogen improves glucose metabolism and insulin signal transduction in HepG2 cells. Clin Exp Pharmacol Physiol. 30:643–648. 2003. View Article : Google Scholar : PubMed/NCBI
13	Zhang HJ, Ji BP, Chen G, Zhou F, Luo YC, Yu HQ, Gao FY, Zhang ZP and Li HY: A combination of grape seed-derived procyanidins and gypenosides alleviates insulin resistance in mice and HepG2 cells. J Food Sci. 74:H1–H7. 2009. View Article : Google Scholar : PubMed/NCBI
14	Xie W, Wang W, Su H, Xing D, Pan Y and Du L: Effect of ethanolic extracts of Ananas comosus L. leaves on insulin sensitivity in rats and HepG2. Comp Biochem Physiol C Toxicol Pharmacol. 143:429–435. 2006. View Article : Google Scholar : PubMed/NCBI
15	Haluzik M, Parízková J and Haluzík MM: Adiponectin and its role in the obesity induced insulin resistance and related complications. Physiol Res. 53:123–129. 2004.PubMed/NCBI
16	Yamashita R, Saito T, Satoh S, Kaburagi Y and Sekihara H: Effects of dehydroepiandrosterone on gluconeogenic enzymes and glucose uptake in human hepatoma cell line, HepG2. Endocr J. 52:727–733. 2005. View Article : Google Scholar : PubMed/NCBI
17	Chavez-Tapia NC, Rosso N and Tiribelli C: In vitro models for the study of non-alcoholic fatty liver disease. Curr Med Chem. 18:1079–1084. 2011. View Article : Google Scholar : PubMed/NCBI
18	Pullinger CR, North JD, Teng BB, Rifici VA, Ronhild de Brito AE and Scott J: The apolipoprotein B gene is constituently expressed in HepG2 cells: Regulation by oleic acid, albumin, and insulin, and measurement of the mRNA half life. J Lipid Res. 30:1065–1077. 1989.PubMed/NCBI
19	Chao PM and Kuo YH, Lin YS, Chen CH, Chen SW and Kuo YH: The metabolic benefits of Polygonum hypoleucum Ohwi in HepG2 cells and Wistar rats under lipogenic stress. J Agric Food Chem. 58:5174–5180. 2010. View Article : Google Scholar : PubMed/NCBI
20	Liu Z, Kuang W, Xu X, Li D, Zhu W, Lan Z and Zhang X: Putative identification of components in Zengye Decoction and their effects on glucose consumption and lipogenesis in insulin-induced insulin-resistant HepG2 cells. J Chromatogr B Analyt Technol Biomed Life Sci. 1073:145–153. 2018. View Article : Google Scholar : PubMed/NCBI
21	Zheng X, Ke Y, Feng A, Yuan P, Zhou J, Yu Y, Wang X and Feng W: The Mechnism by which amentoflavone improves insulin resistance in HepG2 cells. Molecules. 21(pii): E6242016. View Article : Google Scholar : PubMed/NCBI
22	Nie J, Chang Y, Li Y, Zhou Y, Qin J, Sun Z and Li H: Caffeic acid phenethyl ester (Propolis Extract) ameliorates insulin resistance by inhibiting JNK and NF-κB inflammatory pathways in diabetic mice and HepG2 cell models. J Agric Food Chem. 65:9041–9053. 2017. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Horowitz BS, Goldberg IJ, Merab J, Vanni TM, Ramakrishnan R and Ginsberg HN: Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. J Clin Invest. 91:1743–1752. 1993. View Article : Google Scholar : PubMed/NCBI
25	Ruiz M, Frej C, Holmér A, Guo LJ, Tran S and Dahlbäck B: High-density lipoprotein-associated apolipoprotein M limits endothelial inflammation by delivering Sphingosine-1-phosphate to the Sphingosine-1-phosphate receptor 1. Arterioscler Thromb Vasc Biol. 37:118–129. 2017. View Article : Google Scholar : PubMed/NCBI
26	Ruiz M, Okada H and Dahlbäck B: HDL-associated ApoM is anti-apoptotic by delivering sphingosine 1-phosphate to S1P1 & S1P3 receptors on vascular endothelium. Lipids Health Dis. 16:362017. View Article : Google Scholar : PubMed/NCBI
27	Frej C, Mendez AJ, Ruiz M, Castillo M, Hughes TA, Dahlbäck B and Goldberg RB: A shift in ApoM/S1P between HDL-Particles in women with type 1 diabetes mellitus is associated with impaired anti-Inflammatory effects of the ApoM/S1P complex. Arterioscler Thromb Vasc Biol. 37:1194–1205. 2017. View Article : Google Scholar : PubMed/NCBI
28	Lee M, Kim JI, Choi S, Jang Y and Sorn SR: The effect of apoM polymorphism associated with HDL metabolism on obese Korean Adults. J Nutrigenet Nutrigenomics. 9:306–317. 2016. View Article : Google Scholar : PubMed/NCBI
29	Calabro P and Yeh ET: Obesity, inflammation, and vascular disease: The role of the adipose tissue as an endocrine organ. Subcell Biochem. 42:63–91. 2007. View Article : Google Scholar : PubMed/NCBI
30	Xu N, Nilsson-Ehle P, Hurtig M and Ahrén B: Both leptin and leptin-receptor are essential for apolipoprotein M expression in vivo. Biochem Biophys Res Commun. 321:916–921. 2004. View Article : Google Scholar : PubMed/NCBI
31	Luo G, Hurtig M, Zhang X, Nilsson-Ehle P and Xu N: Leptin inhibits apolipoprotein M transcription and secretion in human hepatoma cell line, HepG2 cells. Biochim Biophys Acta. 1734:198–202. 2005. View Article : Google Scholar : PubMed/NCBI
32	Tsubakio-Yamamoto K, Sugimoto T, Nishida M, Okano R, Monden Y, Kitazume-Taneike R, Yamashita T, Nakaoka H, Kawase R, Yuasa-Kawase M, et al: Serum adiponectin level is correlated with the size of HDL and LDL particles determined by high performance liquid chromatography. Metabolism. 61:1763–1770. 2012. View Article : Google Scholar : PubMed/NCBI
33	Altinova AE, Toruner F, Bukan N, Yasar DG, Akturk M, Cakir N and Arslan M: Decreased plasma adiponectin is associated with insulin resistance and HDL cholesterol in overweight subjects. Endocr J. 54:221–226. 2007. View Article : Google Scholar : PubMed/NCBI
34	Zietz B, Herfaah H, Paul G, Ehling A, Müller-Ladner U, Schölmerich J and Schäffler A: Adiponectin represents and independent cardiovascular risk factor predicting serum HDL-C levels in type 2 diabetes. FEBS Lett. 545:103–104. 2003. View Article : Google Scholar : PubMed/NCBI
35	Dullaart RP, de Vries R, van Tol A and Sluiter WJ: Lower plasma adiponectin is a marker of increased intima-media thickness assiciated with type 2 diabetes mellitus and with male gender. Eur J Endocrinol. 156:387–394. 2007. View Article : Google Scholar : PubMed/NCBI
36	Sund NJ, Vatamaniuk MZ, Casey M, Ang SL, Magnuson MA, Stoffers DA, Matschinsky FM and Kaestner KH: Tissue-specific deletion of Foxa2 in pancreatic beta cells results in hyperinsulinemic hypoglycemia. Genes Dev. 15:1706–1715. 2001. View Article : Google Scholar : PubMed/NCBI
37	Lee CS, Friedman JR, Fulmer JT and Kaestner KH: The initiation of liver development is dependent on Foxa transcription factors. Nature. 435:944–947. 2005. View Article : Google Scholar : PubMed/NCBI
38	Wolfrum C, Howell JJ, Ndungo E and Stoffel M: Foxa2 activity increases plasma high density lipoprotein levels by regulating apolipoprotein M. J Biol Chem. 283:16940–16949. 2008. View Article : Google Scholar : PubMed/NCBI